Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pharmexcil
Pharmexcil
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Contract manufacturing in India grows at 20%
SMEs predicted to be main beneficiaries of this growth
India calls off EU trade talks
Action reflects disappointment at EU ban on 700 Indian-made generics
Pharmaceutical
India and China set to dominate biosimilars market
Annual growth rate for biosimilars in India and China could reach 30% in 2014-18
Regulatory obstacles hinder Indian pharma exports to Vietnam
Companies 'red listed' by Vietnamese drug regulatory authority for regulatory non-compliance
Indian pharma exports could miss growth target
Delays in regulatory approvals in North America could halve expected growth rate
Pharmaceutical
Indian pharma to target eastern Europe
Delegation set to promote generics in Hungary, Czech Republic and Romania
Finance
India pharma exports to touch $25bn by 2018
Ability to supply Argentina a major boost to export growth
Subscribe now